{"organizations": [], "uuid": "d91d2d347c810ec563027dc59a7f78a15647b032", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-bristol-myers-squibb-collaborates/brief-bristol-myers-squibb-collaborates-with-janssen-to-develop-commercialize-factor-xia-inhibitors-idUSB8N1KT00R", "country": "US", "domain_rank": 408, "title": "Bristol-Myers Squibb Collaborates With Janssen To Develop & Commercialize Factor XIa Inhibitors", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 1.0, "site_type": "news", "published": "2018-04-17T05:12:00.000+03:00", "replies_count": 0, "uuid": "d91d2d347c810ec563027dc59a7f78a15647b032"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-bristol-myers-squibb-collaborates/brief-bristol-myers-squibb-collaborates-with-janssen-to-develop-commercialize-factor-xia-inhibitors-idUSB8N1KT00R", "ord_in_thread": 0, "title": "Bristol-Myers Squibb Collaborates With Janssen To Develop & Commercialize Factor XIa Inhibitors", "locations": [], "entities": {"persons": [{"name": "janssen", "sentiment": "negative"}], "locations": [], "organizations": [{"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 16 (Reuters) - Bristol-Myers Squibb Co:\n* BRISTOL-MYERS SQUIBB ANNOUNCES WORLDWIDE COLLABORATION WITH JANSSEN TO DEVELOP & COMMERCIALIZE BRISTOL-MYERSâ€™ FACTOR XIA INHIBITOR, BMS-986177\n* BRISTOL-MYERS SQUIBB SAYS JANSSEN WILL PAY CO UPFRONT SUM ALONG WITH POTENTIAL DEVELOPMENT & REGULATORY MILESTONE PAYMENTS\n* BRISTOL-MYERS SQUIBB SAYS CO, JANSSEN EXPECTED TO ADVANCE BMS-986177 INTO PHASE 2 CLINICAL TRIALS IN H2 2018 FOR STUDY OF SECONDARY STROKE PREVENTION Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-17T05:12:00.000+03:00", "crawled": "2018-04-17T00:20:33.017+03:00", "highlightTitle": ""}